Holen Sie sich die Stockscreener-App
0.3514
3.66%
0.0124
Vorhandelsmarkt:
.35
-0.0014
-0.40%
Schlusskurs vom Vortag:
$0.339
Offen:
$0.35
24-Stunden-Volumen:
1.72M
Relative Volume:
3.88
Marktkapitalisierung:
$27.31M
Einnahmen:
$8.23M
Nettoeinkommen (Verlust:
$-32.49M
KGV:
-0.663
EPS:
-0.53
Netto-Cashflow:
$-19.91M
1W Leistung:
-57.53%
1M Leistung:
-58.16%
6M Leistung:
-63.20%
1J Leistung:
-68.90%
1-Tages-Spanne:
$0.33
$0.3962
1-Wochen-Bereich:
$0.292
$0.87
52-Wochen-Spanne:
$0.292
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
Firmenname
Clearside Biomedical Inc
Sektor
Branche
Telefon
678-270-3631
Adresse
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Vergleichen Sie CLSD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.3514 | 64.30M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2025-07-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-18 | Herabstufung | Stifel | Buy → Hold |
| 2024-08-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-15 | Fortgesetzt | Wedbush | Outperform |
| 2021-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-09 | Herabstufung | Needham | Buy → Hold |
| 2018-11-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2018-11-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2018-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-06 | Bestätigt | Needham | Buy |
| 2017-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-02-24 | Eingeleitet | JP Morgan | Overweight |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-10-24 | Bestätigt | Stifel | Buy |
Alle ansehen
Clearside Biomedical Inc Aktie (CLSD) Neueste Nachrichten
Why Clearside Biomedical Inc. stock attracts strong analyst attentionFree Growth Investment Group - Newser
Clearside exploring options to advance suprachoroidal delivery platform - Eyes On Eyecare
What drives Clearside Biomedical Inc. stock priceTremendous return on equity - jammulinksnews.com
Clearside Biomedical announces plan to explore strategic alternatives to advance its proprietary suprachoroidal space (SCS) delivery platform and promising ophthalmology pipeline - Eyes On Eyecare
Is Clearside Biomedical Inc. a good long term investmentExponentially increasing returns - Autocar Professional
Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Target Price at $4.20 - Defense World
Uncovering the Potential of Clearside Biomedical Inc (CLSD) Stock - investchronicle.com
Clearside Biomedical (NASDAQ:CLSD) Downgraded by Stifel Nicolaus to "Hold" - MarketBeat
Chardan Capital Downgrades Clearside Biomedical (NASDAQ:CLSD) to Neutral - Defense World
What analysts say about Clearside Biomedical Inc. stockFast-track wealth growth - Autocar Professional
What institutions are buying Clearside Biomedical Inc. stock nowFree Stock Trading Signals - beatles.ru
Clearside Biomedical Inc. Stock Analysis and ForecastFree Stock Index Interpretation - jammulinksnews.com
Published on: 2025-07-18 21:44:13 - Newser
Health Care Stocks Stumble As Sector Faces Fresh Setbacks - Finimize
Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie - Benzinga
Published on: 2025-07-18 22:42:56 - jammulinksnews.com
This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
CLSD: Downgraded to Neutral by HC Wainwright & Co. | CLSD Stock News - GuruFocus
Why Clearside Biomedical Inc. stock is on top investor watchlistsHigh Return Stock Alerts - Newser
Chardan Capital downgrades Clearside Biomedical stock rating to Neutral By Investing.com - Investing.com Canada
Stifel downgrades Clearside Biomedical stock to Hold on cash concerns By Investing.com - Investing.com Canada
Clearside Biomedical Announces Plan to Explore Strategic - GlobeNewswire
Alpharetta biomedical company ‘exploring strategic alternatives’ as job cuts loom - The Business Journals
Clearside Biomedical shares dip after announcing exploration of strategic alternatives - MSN
Citizens JMP downgrades Clearside Biomedical stock rating as company pauses R&D - Investing.com Canada
Clearside Biomedical's Stock Plummets 25%: Strategic Overhaul or Value Opportunity? - AInvest
Needham downgrades Clearside Biomedical stock to Hold on funding challenges - Investing.com Canada
Clearside Biomedical (CLSD) Downgraded by Needham to Hold | CLSD Stock News - GuruFocus
Clearside Biomedical Explores Strategic Alternatives Amid Economic Challenges - TipRanks
Clearside Biomedical stock falls after announcing strategic alternatives exploration By Investing.com - Investing.com South Africa
Clearside Biomedical (CLSD) Adopts Strategic Measures Amid Econo - GuruFocus
Clearside Biomedical To Explore Strategic Alternatives - Nasdaq
Clearside Biomedical to explore strategic alternatives amid cash concerns - Investing.com
Clearside Biomedical, Inc. Explores Strategic Alternatives to Advance SCS Delivery Platform and CLS-AX Development for Retinal Diseases - Quiver Quantitative
Clearside Biomedical Explores Strategic Options with FDA-Approved Eye Drug Platform | CLSD Stock News - Stock Titan
How Clearside Biomedical Inc. stock performs during market volatilityFree Risk Assessment Services - Newser
What makes Clearside Biomedical Inc. stock price move sharplyFree Stock Market Knowledge Sharing - Newser
Finanzdaten der Clearside Biomedical Inc-Aktie (CLSD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):